Board Member
Metagenomi Therapeutics, Inc. (MGX)Board Member
Cerus Corp (CERS)Equibles does not estimate personal net worth.
Get an email with a short summary when Mirum Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get MIRM alertsEric Bjerkholt is recorded as CFO at Mirum Pharmaceuticals, Inc. (MIRM), Board Member at Metagenomi Therapeutics, Inc. (MGX) and Board Member at Cerus Corp (CERS) since January 1, 2018. The newest filing on record that lists Eric Bjerkholt as CFO at Mirum Pharmaceuticals, Inc. (MIRM) is dated April 23, 2024. The newest filing on record that lists Eric Bjerkholt as Board Member at Metagenomi Therapeutics, Inc. (MGX) is dated April 27, 2026. Metagenomi Therapeutics, Inc. reported in an 8-K filed January 16, 2025 that Eric Bjerkholt was appointed director, effective January 27, 2025. Cerus Corp reported in an 8-K filed June 11, 2024 a re-election or new board role (Director) for Eric Bjerkholt, on the board since at least 2018, effective June 5, 2024. Mirum Pharmaceuticals, Inc. reported in an 8-K filed September 11, 2023 that Eric Bjerkholt was appointed Chief Financial Officer, effective September 11, 2023. The proxy statement of Mirum Pharmaceuticals, Inc. reports total compensation of $3,246,216 for Eric Bjerkholt in fiscal 2025, including a base salary of $520,000. Disclosed compensation is on record for 4 fiscal years. Eric Bjerkholt has spoken on 12 earnings calls and 2 other investor events across 1 company, most recently for Mirum Pharmaceuticals, Inc. on November 11, 2026. Mirum Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Cerus Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Mirum Pharmaceuticals, Inc. includes Christopher Peetz (CEO), Michael Grey (CEO), Peter Radovich (COO) and 5 others.
“approved an increase in the size of the Board from five directors to six directors and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Eric Bjerkholt to serve as a director of the Board, each effective as of January 27, 2025”
“The Company's stockholders elected each of the three nominees named below to the Board of Directors to serve until the 2027 Annual Meeting of Stockholders or until his respective successor has been duly elected and qualified.”
“We will be making forward-looking statements, so please refer to our risk factors in our SEC filings. So we now have four approved medicines. We're experiencing really rapid revenue growth.”
“And first of all, thank you to Wolf Research for hosting us. And let me remind you that we will be making forward-looking statements, so please look at the risk factors in our regulatory filings.”
“Our third quarter financial performance reflects our ongoing operating priorities. Continued top-line growth with focused investments in bringing our late-stage programs through several potential approvals and launches.”
“Today, I'll walk through the financials of another excellent quarter for Mirim. Net product sales for the second quarter were $176 million compared to net product sales of $128 million in the second quarter of last year.”
“Today, I'll walk you through the financials for the quarter, including an overview of the impact of the Blue Jay acquisition and the Zalogi circuit transaction.”
2018-01-01–present
Last confirmed April 22, 2026
Start not stated–present
Last confirmed April 23, 2024
Start not stated–present
Last confirmed April 27, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Mirum Pharmaceuticals, Inc. (MIRM) | Chief Financial Officer | $520,000 | $3,246,216 |
| 2024 | Mirum Pharmaceuticals, Inc. (MIRM) | Chief Financial Officer | $500,000 | $2,006,255 |
| 2023 | Mirum Pharmaceuticals, Inc. (MIRM) | Chief Financial Officer | $151,562 | $4,337,928 |
| 2022 | Mirum Pharmaceuticals, Inc. (MIRM) | Chief Financial Officer | — | — |
